We are live on ! Find out more
ATXS

Astria Therapeutics
ATXS

Delisted

ATXS was delisted on the 22nd of January, 2026.

Back to rankings

0 hedge funds and large institutions have $0 invested in Astria Therapeutics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 140 closing their positions.

New
Increased
Maintained
Reduced
Closed

99.02% less ownership

Funds ownership: 99.02% → 0% (-99%)

100% less funds holding

Funds holding: 141 → 0 (-141)

100% less capital invested

Capital invested by funds: $738M → $0 (-$738M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 140

Holders
–
Holders Change
-141
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
140
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$84.9M
2
BlackRock
BlackRock
New York
-$50.2M
3
GCL
Glazer Capital LLC
New York
-$49.4M
4
MF
Magnetar Financial
Illinois
-$44.9M
5
UBS Group
UBS Group
Switzerland
-$31.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
– -$9.36M -714,679 Closed
Goldman Sachs
27
Goldman Sachs
New York
– -$9.34M -713,821 Closed
BOA
28
Birnam Oak Advisors
New York
– -$9.03M -689,735 Closed
AA
29
AQR Arbitrage
Connecticut
– -$8.21M -627,293 Closed
WIC
30
Water Island Capital
New York
– -$8.06M -615,790 Closed
GCIA
31
Gabelli & Co Investment Advisers
New York
– -$7.61M -581,550 Closed
Millennium Management
32
Millennium Management
New York
– -$6.99M -534,054 Closed
CCM
33
Chicago Capital Management
Illinois
– -$5.24M -530,000 Closed
PCM
34
Prelude Capital Management
New York
– -$6.92M -529,021 Closed
AA
35
ABC Arbitrage
France
– -$6.77M -517,207 Closed
Marshall Wace
36
Marshall Wace
United Kingdom
– -$5.31M -405,700 Closed
GF
37
Gabelli Funds
New York
– -$5.25M -401,450 Closed
Charles Schwab
38
Charles Schwab
California
– -$4.97M -380,042 Closed
Hudson Bay Capital Management
39
Hudson Bay Capital Management
Connecticut
– -$4.8M -366,340 Closed
Northern Trust
40
Northern Trust
Illinois
– -$4.67M -356,779 Closed
SFM
41
Sphera Funds Management
Israel
– -$4.66M -355,725 Closed
OBAM
42
ODDO BHF Asset Management
France
– -$4.15M -317,300 Closed
DCM
43
DAFNA Capital Management
California
– -$3.99M -304,775 Closed
AIMCA
44
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
– -$3.57M -272,750 Closed
SSA
45
Schonfeld Strategic Advisors
New York
– -$3.18M -242,952 Closed
Dimensional Fund Advisors
46
Dimensional Fund Advisors
Texas
– -$2.94M -224,658 Closed
CF
47
Cantor Fitzgerald
New York
– -$2.93M -224,077 Closed
Renaissance Technologies
48
Renaissance Technologies
New York
– -$2.7M -205,961 Closed
QL
49
Quarry LP
New York
– -$2.47M -188,988 Closed
ACM
50
ADAR1 Capital Management
Texas
– -$2.27M -173,557 Closed
1
2
3 4 5

ATXS Hedge Fund Activity: Q1 2026 in Review

0 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2026, worth a combined $0 — down 100% from $738M a quarter earlier.

Sellers outnumbered buyers: 140 funds closed out of ATXS and 0 opened new positions — a net loss of 140 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Perceptive Advisors, exiting entirely with an estimated $84.9M sold.

  • 0 institutional investors held Astria Therapeutics (ATXS) as of Q1 2026, down from 141 in Q4 2025.
  • Funds reported $0 of Astria Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Astria Therapeutics positions in Q1 2026 and 140 closed out, a net change of -140 holders.
  • The largest Astria Therapeutics seller in Q1 2026 was Perceptive Advisors, an estimated $84.9M sold.

Based on aggregated 13F filings for Q1 2026.